Evidence map›Paper›PMID 41968837›Full record

ArticleMolecular imaging and radionuclide therapy2026

Berna Okudan, Refia Yükseltürk, Mustafa Özdemir

Abstract read
In one paragraph

Article in Molecular imaging and radionuclide therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Berna OkudanUniversity of Health Sciences Türkiye, Ankara City Hospital, Clinic of Nuclear Medicine, Ankara, Türkiye.ORCID 0000-0001-8076-3988
Refia YükseltürkUniversity of Health Sciences Türkiye, Ankara City Hospital, Clinic of Nuclear Medicine, Ankara, Türkiye.ORCID 0000-0002-4515-9707
Mustafa ÖzdemirUniversity of Health Sciences Türkiye, Ankara City Hospital, Clinic of Radiology, Ankara, Türkiye.ORCID 0000-0001-9513-6768

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mediastinal paragangliomas (PGLs) are extremely rare neuroendocrine tumors. Clinical presentation varies and tumor resection can be challenging due to bleeding and risk of catecholamine surges in functional tumors. We report on a case 68 with a DOTATATE avid mediastinal mass which was histopathologically confirmed as a PGL that was fed by the coronary artery in whole-body positron emission tomography/computed tomography imaging using gallium-68-DOTATATE.

Indexed as

177Lu-DOTATATE68Ga-DOTATATEneuroendocrine tumorParagangliomaPET/CT

Identifiers

PMID41968837
PMCPMC13640804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.